DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain

Zeitschrift für Rheumatologie
W W BoltenKommission Pharmakotherapie der DGRh

Abstract

NSAIDs exert their anti-inflammatory and analgesic effects by inhibition of COX‑2, a key enzyme for proinflammatory prostanoid synthesis. Therapy with NSAIDs is limited by their typical gastrointestinal, cardiovascular and renal side effects, which are caused by inhibition of COX‑1 (gastrointestinal toxicity), COX‑2 (cardiovascular side effects) or both COX-isoenzymes (renal side effects). Appropriate prevention strategies should be employed in patients at risk. If gastrointestinal risk factors are present, co-administration of a proton pump inhibitor or misoprostol is recommended; in patients with cardiovascular risk, coxibs, diclofenac and high-dose ibuprofen should be avoided. Furthermore, drug interactions and contraindications should be considered. In patients with renal impairment (GFR < 30 ml/min) all NSAIDs must be avoided. Ulcer anamnesis is a contraindication for traditional NSAIDs. Preexisting cardio- or cerebrovascular diseases are contraindications for coxibs. Treatment decisions should be individually based with a continuous monitoring of the risk - benefit ratio and exploitation of non-pharmacological treatment options.

References

Mar 1, 1984·The New England Journal of Medicine·D M Clive, J S Stoff
May 24, 1997·BMJ : British Medical Journal·H McQuayD Justins
Aug 5, 1998·Alimentary Pharmacology & Therapeutics·G Bianchi PorroM Petrillo
Nov 20, 1998·BMJ : British Medical Journal·J Hardy
Dec 1, 1999·British Journal of Pharmacology·J A Mitchell, T D Warner
Jul 25, 2000·The Cochrane Database of Systematic Reviews·A RostomJ McGowan
Sep 7, 2000·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·G Bianchi PorroT Santagada
Nov 23, 2000·The New England Journal of Medicine·C BombardierUNKNOWN VIGOR Study Group
Feb 13, 2001·The American Journal of Medicine·J Brun, R Jones
Jun 28, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·E NiederbergerG Geisslinger
Oct 20, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·I TegederG Geisslinger
Dec 26, 2001·The New England Journal of Medicine·F Catella-LawsonG A FitzGerald
Mar 23, 2002·The American Journal of Cardiology·Claire Bombardier
Jun 5, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Justine HenaoKarlene Hewan-Lowe
Dec 27, 2002·The New England Journal of Medicine·Francis K L ChanJoseph J Y Sung
Jan 10, 2003·The Cochrane Database of Systematic Reviews·A RostomJ McGowan
Feb 25, 2003·Lancet·T M MacDonald, L Wei
Dec 3, 2003·Annals of the Rheumatic Diseases·K M JordanUNKNOWN Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT
May 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Timothy D Warner, Jane A Mitchell
Jul 29, 2004·Mini Reviews in Medicinal Chemistry·D O Stichtenoth
Aug 20, 2004·Pharmacological Reviews·Daniel L SimmonsTimothy Hla
Oct 9, 2004·Annals of the Rheumatic Diseases·W ZhangUNKNOWN EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Feb 16, 2005·Archives of Internal Medicine·Tai-Juan AwHenry Krum
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Feb 17, 2005·The New England Journal of Medicine·Nancy A NussmeierKenneth M Verburg
Mar 9, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Consuelo HuertaLuis Alberto García Rodríguez

❮ Previous
Next ❯

Citations

Jul 16, 2016·Zeitschrift für Rheumatologie·W W Bolten, K Krüger
Nov 12, 2021·Der Schmerz·A T HoffmannF Brinkmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.